文献速递淋巴瘤

滤泡性淋巴瘤原发治疗与生存的分期趋势:荷兰全国人群研究1989-2016

Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016.
PubMed 文献 · Leukemia · 2020-10-12

该研究基于荷兰全国人群数据,纳入1989-2016年确诊的12372例成人滤泡性淋巴瘤患者,分析不同分期原发治疗与相对生存的趋势。结果显示,自2003年利妥昔单抗引入后相对生存显著改善,尤其III-IV期和老年患者,但老年晚期患者仍有改善空间。

要点

  • I期滤泡性淋巴瘤放疗使用率随时间及年龄组相对稳定,2009-2016年三个年龄组分别为66%、54%、49%。
  • II-IV期患者诊断后12个月内开始化疗的比例下降,反映观察等待策略更广泛应用。
  • 2003年后相对生存显著改善,但老年III-IV期患者生存仍较低,2009-2016年5年相对生存仅68%。

核心结论

  • 自2003年利妥昔单抗引入以来,滤泡性淋巴瘤相对生存显著改善,尤其III-IV期和老年患者,但老年晚期患者仍有改善空间。

研究设计与样本

  • 基于荷兰全国人群的回顾性分析,纳入1989-2016年确诊的12372例成人滤泡性淋巴瘤患者,中位年龄62岁,I期占21%。
  • 按疾病分期分层,并分为四个日历时期(1989-1995、1996-2002、2003-2008、2009-2016)和三个年龄组(18-60、61-70、>70岁)。

主要发现

  • I期滤泡性淋巴瘤放疗使用率随时间及三个年龄组相对稳定,2009-2016年分别为66%、54%、49%。
  • II-IV期患者诊断后12个月内开始化疗的比例随时间下降,表明观察等待策略更广泛应用。
  • 相对生存随时间显著改善,尤其自2003年利妥昔单抗引入后,以及III-IV期和老年组。
  • 2009-2016年,I-II期 vs III-IV期5年相对生存:18-60岁组96% vs 90%,61-70岁组93% vs 83%,>70岁组92% vs 68%。

临床怎么用

  • 对于I期滤泡性淋巴瘤,放疗仍是主要治疗选择之一,使用率在不同年龄组间有差异。
  • II-IV期患者可更广泛地采用观察等待策略,避免过早化疗。
  • 利妥昔单抗的引入显著改善了滤泡性淋巴瘤生存,尤其晚期和老年患者。
  • 老年III-IV期患者生存改善仍不理想,需关注该人群的治疗优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We assessed stage-specific trends in primary therapy and relative survival among adult follicular lymphoma (FL) patients diagnosed in the Netherlands between 1989-2016 (N = 12,372; median age, 62 years; and 21% stage I disease). Patients were stratified by disease stage and subsequently categorized into four calendar periods (1989-1995, 1996-2002, 2003-2008, and 2009-2016) and three age groups (18-60, 61-70, and >70 years). The use of radiotherapy in stage I FL remained relatively stable over time and across the three age groups (i.e., 66%, 54%, and 49% in 2009-2016, respectively). In stage II-IV FL, the start of chemotherapy within 12 months post-diagnosis decreased over time, indicating a broader application of a watch-and-wait approach. Relative survival improved considerably over time, especially since 2003 when rituximab was introduced in the Netherlands, and for stage III-IV FL patients and older age groups. Five-year relative survival for patients with stage I-II versus stage III-IV FL in the period 2009-2016 was 96% versus 90%, 93% versus 83%, and 92% versus 68% across the three age groups, respectively. Collectively, the improvement in survival since 2003 is accounted for by advances in FL management, particularly the implementation of rituximab. There remains, however, room for improvement among elderly stage III-IV FL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dinnessen MAW, van der Poel MWM, Tonino SH, et al. Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016. Leukemia. 2020. PMID: 33046819. doi:10.1038/s41375-020-01048-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。